JPWO2024085166A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2024085166A5
JPWO2024085166A5 JP2024551825A JP2024551825A JPWO2024085166A5 JP WO2024085166 A5 JPWO2024085166 A5 JP WO2024085166A5 JP 2024551825 A JP2024551825 A JP 2024551825A JP 2024551825 A JP2024551825 A JP 2024551825A JP WO2024085166 A5 JPWO2024085166 A5 JP WO2024085166A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
cldn4
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024551825A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024085166A1 (cg-RX-API-DMAC7.html
JP7730432B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/037616 external-priority patent/WO2024085166A1/ja
Publication of JPWO2024085166A1 publication Critical patent/JPWO2024085166A1/ja
Publication of JPWO2024085166A5 publication Critical patent/JPWO2024085166A5/ja
Application granted granted Critical
Publication of JP7730432B2 publication Critical patent/JP7730432B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024551825A 2022-10-19 2023-10-18 がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用 Active JP7730432B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022167362 2022-10-19
JP2022167362 2022-10-19
PCT/JP2023/037616 WO2024085166A1 (ja) 2022-10-19 2023-10-18 がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用

Publications (3)

Publication Number Publication Date
JPWO2024085166A1 JPWO2024085166A1 (cg-RX-API-DMAC7.html) 2024-04-25
JPWO2024085166A5 true JPWO2024085166A5 (cg-RX-API-DMAC7.html) 2025-06-27
JP7730432B2 JP7730432B2 (ja) 2025-08-27

Family

ID=90737914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551825A Active JP7730432B2 (ja) 2022-10-19 2023-10-18 がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用

Country Status (10)

Country Link
EP (1) EP4606384A1 (cg-RX-API-DMAC7.html)
JP (1) JP7730432B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250089513A (cg-RX-API-DMAC7.html)
CN (1) CN119997975A (cg-RX-API-DMAC7.html)
AU (1) AU2023365438A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025001156A1 (cg-RX-API-DMAC7.html)
IL (1) IL319946A (cg-RX-API-DMAC7.html)
MX (1) MX2025004457A (cg-RX-API-DMAC7.html)
TW (1) TW202426503A (cg-RX-API-DMAC7.html)
WO (1) WO2024085166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026042803A1 (ja) * 2024-08-21 2026-02-26 アステラス製薬株式会社 がん治療におけるプラチナ系薬剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
BR112015007184A2 (pt) 2012-10-02 2017-08-08 Bristol Myers Squibb Co combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
MX380176B (es) * 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
BR112018071612A2 (pt) * 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
CN116133684B (zh) 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody

Similar Documents

Publication Publication Date Title
US10913796B2 (en) Antibodies targeting Fc receptor-like 5 and methods of use
JP7150880B2 (ja) 抗-b7-h3抗体およびその用途
US9988450B2 (en) Anti-PD1 antibodies and their use as therapeutics and diagnostics
JP2023539245A5 (cg-RX-API-DMAC7.html)
JP7649744B2 (ja) Btn3a結合タンパク質及びその使用
JP2020180158A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
JP2021503455A5 (cg-RX-API-DMAC7.html)
JP2023506184A5 (cg-RX-API-DMAC7.html)
JP2023543031A5 (cg-RX-API-DMAC7.html)
JP2017536341A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2018518540A5 (cg-RX-API-DMAC7.html)
WO2016197497A1 (zh) 一种抗pd-1的单克隆抗体及其获得方法
JP2022545647A5 (cg-RX-API-DMAC7.html)
JP2021524478A5 (cg-RX-API-DMAC7.html)
JP2023551027A5 (cg-RX-API-DMAC7.html)
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP2021530244A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2023529842A5 (cg-RX-API-DMAC7.html)